CDK12/13 promote splicing of proximal introns by enhancing the interaction between RNA polymerase II and the splicing factor SF3B1

V Panzeri, M Pieraccioli, E Cesari… - Nucleic Acids …, 2023 - academic.oup.com
Transcription-associated cyclin-dependent kinases (CDKs) regulate the transcription cycle
through sequential phosphorylation of RNA polymerase II (RNAPII). Herein, we report that …

The splicing factor PTBP1 promotes expression of oncogenic splice variants and predicts poor prognosis in patients with non–muscle-invasive bladder cancer

P Bielli, V Panzeri, R Lattanzio, S Mutascio… - Clinical Cancer …, 2018 - AACR
Purpose: Non–muscle-invasive bladder cancer (NMIBC) is a malignant disease characterized
by high heterogeneity, which corresponds to dysregulated gene expression and …

c-MYC empowers transcription and productive splicing of the oncogenic splicing factor Sam68 in cancer

C Caggiano, M Pieraccioli, V Panzeri… - Nucleic acids …, 2019 - academic.oup.com
The splicing factor Sam68 is upregulated in many human cancers, including prostate cancer
(PCa) where it promotes cell proliferation and survival. Nevertheless, in spite of its frequent …

[HTML][HTML] The oncogenic kinase NEK2 regulates an RBFOX2-dependent pro-mesenchymal splicing program in triple-negative breast cancer cells

…, M De Musso, F Delle Monache, V Panzeri… - Journal of Experimental …, 2021 - Springer
Background Triple-negative breast cancer (TNBC) is the most heterogeneous and malignant
subtype of breast cancer (BC). TNBC is defined by the absence of expression of estrogen, …

[HTML][HTML] SEMA6C: a novel adhesion-independent FAK and YAP activator, required for cancer cell viability and growth

D Fard, E Testa, V Panzeri, S Rizzolio… - Cellular and Molecular …, 2023 - Springer
Transmembrane semaphorins are signaling molecules, controlling axonal wiring and embryo
development, which are increasingly implicated in human diseases. Semaphorin 6C (…

The RNA‐binding protein MEX3A is a prognostic factor and regulator of resistance to gemcitabine in pancreatic ductal adenocarcinoma

V Panzeri, I Manni, A Capone, C Naro… - Molecular …, 2021 - Wiley Online Library
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer. Most patients
present with advanced disease at diagnosis, which only permits palliative chemotherapeutic …

[HTML][HTML] Alternative polyadenylation of ZEB1 promotes its translation during genotoxic stress in pancreatic cancer cells

I Passacantilli, V Panzeri, P Bielli, D Farini… - Cell Death & …, 2017 - nature.com
Pancreatic ductal adenocarcinoma (PDAC) is characterized by extremely poor prognosis. The
standard chemotherapeutic drug, gemcitabine, does not offer significant improvements for …

[HTML][HTML] Functional interaction between the oncogenic kinase NEK2 and Sam68 promotes a splicing program involved in migration and invasion in triple-negative …

…, C Caggiano, M De Musso, V Panzeri… - Frontiers in …, 2022 - frontiersin.org
Triple-negative breast cancer (TNBC) represents the most aggressive breast cancer subtype.
Poor prognosis in TNBC is partly due to lack of efficacious targeted therapy and high …

[HTML][HTML] RNA extraction from endoscopic ultrasound-acquired tissue of pancreatic cancer is feasible and allows investigation of molecular features

L Archibugi, V Ruta, V Panzeri, M Redegalli… - Cells, 2020 - mdpi.com
Transcriptome analyses allow the distinguishing of pancreatic ductal adenocarcinoma (PDAC)
subtypes, exhibiting different prognoses and chemotherapy responses. However, RNA …

[HTML][HTML] A new Phe-free protein substitute engineered to allow a physiological absorption of free amino acids for phenylketonuria

N Giarratana, G Gallina, V Panzeri, A Frangi… - Journal of Inborn …, 2018 - SciELO Brasil
An innovative technology (Physiomimic Technology) has been applied to amino acids (AAs)
formulated for patients with phenylketonuria, with the objective of masking AA taste and …